Potent, selective non-peptide oxytocin receptor (OTR) agonist (Ki
= 58.4 nM at human OTR). Exhibits anxiolytic-like effects. May have therapeutic potential for the treatment of psychosis and schizophrenia.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.
Ring et al.